Start Recovering Now

Enhances Stroke Recovery and Supports

Neurological Functions

Stroke has a devastating impact on million of lives

Stroke is the leading cause of adult disability worldwide

• A stroke occurs every 2 seconds

• 15 Million strokes per year (2/3 only partial recovery)

Patients are left without a treatment

• Neuroprotective agents have not (yet) delivered their promise

• Hyper acute intravenous thrombolysis available only to a minority of

patients

• Lack of pharmacological modalities to support post stroke recovery

• Patients grow desperate and frustrated

Interest to look at new sources of therapeutics

• Biopharmaceutical company incorporated in 2003 • By a group of renown scientists from east and west and businessmen. • Focus on safety, quality and clinical data • Offices in Singapore and Paris • Important involvement & initiative of academic/key opinion leaders & clinicians.

SCIENTIFIC ADVISORY BOARD, MEDICAL EXPERTS AND INVESTIGATORS

TCM understanding, Biology and EBM expertise,

Georges Charpak

Nobel Laureate Etienne Beaulieu

Former President,

French Academy

of Sciences

Michel Lazdunski

Director Pharmacology,

CNRS

Acad. Shi Xuemin

Tianjin First Teaching

Hospital of TCM

Acad Han Ji Sheng

Beijing

Neuroscience Inst.

Prof. Zhao Guo Ping

Shanghai Genome

Center

MG Bousser

Advisor on Stroke and

Migraine(France)

Pr Geoffrey Donnan

National Stroke

Institute, University of

Melbourne, Australia

Dr Christopher CHEN

Singapore

National University of

Singapore

“Moleac introduced in the

market NeuroAiD™, the first

treatment that brings faster and

fuller recovery for stroke

patients...”

“Moleac receives the Frost &

Sullivan Asia Pacific Excellence in

Healthcare Award for the success

of its stroke treatment drug

NeuroAiD™...”

Awards recognitions

NeuroAiD™ treatment

Introduction to NeuroAiD™

• NeuroAiD™ is a post stroke recovery medicine for faster and fuller neurological

recovery

• It aids in recovering your independence and reducing neurological deficits

• Effective at early and late stage of stroke as an add-on treatment

• Strong clinical data on efficacy and safety

• 0.5 million patients in 25 countries

Details

• 3 months treatment recommended . Results usually observed within one month

• Capsule form - (can be opened and diluted in water or administrated via gastric tube)

• NeuroAiD™ should be initiated as soon as possible post stroke and it has shown to be

effective up to at least 6 months post stroke.

Aimed at long term reduction of disabilities after a stroke

How NeuroAiD™ improves

SPEECH – case study in

European Neurology journal

reports several improvements

of vision disabilities, with

resolution of anomia and

aphasia.

MOTOR – Stroke publication

reports that patients on

NeuroAiD™ showed a 25%

higher recovery in motor

deficits after one month

treatment.

VISION – case study in

European Neurology journal

reports several improvements

of vision disabilities, with

resolution of diplopia and

hemianopia.

Clinical trials and number of case reports

demonstrated improvements in :

- Motor functions,

- Speech (anomia, aphasia)

- Vision (hemianopia, diplopia)

- Other cognitive.

Introduction to NeuroAiD™

Footage

• NeuroAiD™ commercialization is pursued through a network of affiliates

• In the European Union our subsidiaries in Paris prepare the registration

• We are pursuing exponential geographic expansion

2007 2008 2009 2010 2011

Singapore Malaysia Pakistan Argentina

Iran

Jordan

Lebanon

Iraq

Thailand Philippines

Vietnam

Indonesia

Algeria

Russia

Mexico

Lebanon

Europe

Eastern Europe

CIS

USA

Middle-East

Korea…

NeuroAiD™ in stroke treatment

NeuroAiD™ has shown efficacy in acute and late post-stroke stage.

4 - 5 hours First day 1 week 6 months

Hyper acute therapies such as: rTPA

Window to start the treatment with NeuroAiD™

Acute stage Late stage

Stroke onset

24 hours

Rehabilitation

Publications

Medical marketing – Publications

Scientific publications

• 7 recent publications summarize NeuroAiD™’s efficacy data, pharmacology data and excellent

tolerability :

– Neuropharmacology in 2010 – Pharmacology data

– Cerebrovascular Diseases in 2010 - Safety data in acute stage

– Cerebrovascular Diseases TIERS in 2009 – Pilot study

– Stroke Journal in 2009 – Efficacy trial

– European Neurology in 2008 – Case report

– Cerebrovascular Diseases in 2008 – Safety trial

– The International Journal of Stroke in 2009 – The CHIMES

protocol

Summary of existing clinical evidence

• Pharmacological data show neuroproliferative, neuroregenerative and

neuroprotective properties

• Patients on NeuroAiD™ had 2.4 times more chances to achieve independence

after one month of treatment

• Patients on NeuroAiD™ showed a 25% higher recovery in the motor components

• Many studies and case reports (even at late stage of stroke onset) show good

recovery in motor function, balance, visual and speech functions for patients taking

NeuroAiD™

•NeuroAiD™ does not modify hematological, hemostatic, and biochemical and

ECG parameters in normal subjects and stroke patients

Clinical Trials

14

Clinical trials

Clinical trials

CHIMES sites

R & D

Clinicians leading the CHIMES trial

Prof MG BOUSSER

Hôpital Lariboisière

France

Prof. Geoffrey DONNAN National Stroke Institute – University of Melbourne Australia

Prof David MACHIN CTERU Singapore

Prof Christophe TZOURIO Paris - France

DMSB

Dr Christopher CHEN

National University

Singapore

CTERU (academic CRO) Dr Tan Say Beng Clinical Trials and Epidemiology Research Unit

4 Centres recruiting: University of Santo Tomas, Jose Reyes Medical Centre, Davao Medical Center; Philippines General Hospital Prof Jose NAVARRO, Dr Alejandro C. BAROQUE, Dr Hil Gan, Dr Annabelle Lao Dr Carlos I Chua (PI) Dr Cristina M San Jose

All 4 centres: NUH SGH, TTSH, CGH Dr N.V. RAMANI, Dr Sherry Young, Dr. Bernard CHAN, Dr CHANG Hui Meng Dr Rajinder Singh

SINGAPORE PHILIPPINES

5 Centres Siriraj Hospital Chiangmai University Hospital Chulalongkorn Hospital King Mongkutla Hospital Thammasat Hospital

THAILAND

Prof Niphon Poungvarin Dr Siwaporn Chankrachang Dr Nijasri Suwanwela, Dr Samart Nidhinandana Dr Sombat Muengtaweepongsa

More centres in discussion in • Pakistan • Indonesia • Malaysia • Hong Kong

� Chimes provides an important platform

� Access to leading clinicians / further data on NeuroAiD™ when started within 72h after stroke onset

SRI LANKA

Dr Asita da Silva University of Kelaniya

Thank You

Find out more

www.neuroaid.com